$48.52-0.52 (-1.06%)
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Kiniksa Pharmaceuticals International, plc in the Healthcare sector is trading at $48.52 with a market capitalization of $3.7B. Wall Street consensus targets $63.50 (8 analysts), implying a +30.9% move over the next 12 months. The stock is currently 19% below its 52-week high of $59.87, remaining 12.0% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokin...
The United States market has shown robust performance recently, with a 1.2% increase over the past week and a substantial 29% rise over the last year, while earnings are projected to grow by 17% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on current technological trends but also demonstrate strong potential for sustained revenue and earnings growth.
Kiniksa Pharmaceuticals is gaining momentum after strong ARCALYST sales growth, raised revenue guidance, and optimism surrounding its next-generation pipeline
Kiniksa Pharmaceuticals International, plc's ( NASDAQ:KNSA ) strong earnings report was rewarded with a positive stock...
Kiniksa Pharmaceuticals International, plc reported past first-quarter 2026 results with revenue of US$214.27 million and net income of US$22.59 million, alongside basic earnings per share from continuing operations of US$0.30. The company also raised its 2026 net product revenue outlook to a range of US$930 million to US$945 million, signaling increased confidence in its ARCALYST franchise and broader portfolio execution. We’ll now examine how Kiniksa’s raised 2026 revenue guidance shapes...
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is one of the best drug stocks to buy according to analysts. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced its fiscal Q1 2026 financial results on April 28 and also provided updates regarding its recent portfolio execution. The company reported that net product revenue for ARCALYST® in fiscal Q1 2026 reached […]